Table 1 Patients characteristics stratified by cohort (PBT and CRT) before and after propensity matching
Before propensity score matching (n = 235) | After propensity score matching (n = 52) | |||||
|---|---|---|---|---|---|---|
PBT (n = 26) | CRT (n = 209) | p value | PBT (n = 26) | CRT (n = 26) | p value | |
Age (y), mean ± SD | 57.6 ± 12.3 | 62.5 ± 13.1 | 0.075 | 57.6 ± 12.3 | 54.3 ± 14.3 | 0.37 |
Sex, female (%) | 11 (42.3%) | 87 (41.6%) | 1.000 | 11 (42.3%) | 7 (26.9%) | 0.382 |
Tumor location (cerebral lobe) (%) | 25 (96.2%) | 171 (81.8%) | 0.090 | 25 (96.2%) | 26 (100%) | 1 |
Extent of resection (GTR, STR) (%) | 23 (88.5%) | 122 (58.4%) | 0.002 | 23 (88.5%) | 19 (73.1%) | 0.291 |
Temozolomide (%) | 26 (100%) | 205 (98.1%) | 1.000 | 26 (100%) | 25 (96.2%) | 1 |
Immunotherapy (%) | 5 (19.2%) | 22 (10.5%) | 0.195 | 5 (19.2%) | 6 (23.1%) | 1 |
KPS (pre RT) ≥ 70 (%) | 23 (88.5%) | 140 (67.0%) | 0.025 | 23 (88.5%) | 22 (84.6%) | 1 |
MGMT methyl (%) | 1/21 (4.8%) | 47/146 (32.2%) | 0.009 | 1/21 (4.8%) | 3/18 (16.7%) | 0.318 |
IDH mut (%) | 3/23 (13.0%) | 9/181 (5.0%) | 0.140 | 3/23 (13.0%) | 1/18 (5.6%) | 0.618 |